Download Reference list - Simdax® (levosimendan

September 2013
1 (6)
Reference list - Simdax® (levosimendan) selection of publications
= new or updated reference
HEART FAILURE
• GENERAL
Packer M, Colucci W, Fisher L, et al.
Effect of levosimendan on the short-term clinical course of
patients with acutely decompensated heart failure.
J Am Coll Cardiol HF 2013;1:103-111.
Giglioli C, Cecchi E, Landi D, et al.
Levosimendan produces an additional clinical and hemo­
dynamic benefit in patients with decompensated heart
failure successfully submitted to a fluid removal treatment.
Congest Heart Fail 2012;18:47-53.
Aidonidis G, Kanonidis I, Koutsimanis V, et al.
Efficiency and safety of prolonged levosimendan infusion
in patients with acute heart failure.
Cardiol Res Pract 2011;Mar 31:342302.
Feola M, Lombardo E, Taglieri C, et al.
Effects of levosimendan/furosemide infusion on plasma
brain natriuretic peptide, echocardiographic parameters
and cardiac output in end-stage heart failure patients.
Med Sci Monit 2011;17:17-13.
Lunghetti S, Palmerini E, Urselli R, et al.
Effects of levosimendan without loading dose on systolic
and diastolic function in patients with end-stage heart
failure.
Cardiol J 2011;18:532-537.
Bergh C-H, Andersson B, Dahlström U, et al.
Intravenous levosimendan vs. dobutamine in acute
decompensated heart failure patients on beta-blockers.
Eur J Heart Fail 2010;12:404-410.
Branzi G, Malfatto G, Villani A, et al.
Acute effects of levosimendan on mitral regurgitation
and diastolic function in patients with advanced chronic
heart failure.
J Cardiovasc Med 2010;11:662-668.
Farmakis D, Parissis JT, Bistola V, et al.
Plasma B-type natriuretic peptide reduction predicts
long-term response to levosimendan therapy in acutely
decompensated chronic heart failure.
Int J Cardiol 2010;139:75-79.
Kivikko M, Sundberg S, Karlsson MO, et al.
Acetylation status does not affect levosimendan’s
hemodynamic effects in heart failure patients.
Scand Cardiovasc J 2011;45:86-90.
Cohen-Solal A, Logeart D, Huang B, et al.
Lowered B-type natriuretic peptide in response to
levosimendan or dobutamine treatment is associated with
improved survival in patients with severe acutely
decompensated heart failure.
J Am Coll Cardiol 2009;53:2343-2348.
Mebazaa A, Nieminen MS, Filippatos GS, et al.
Levosimendan vs. dobutamine: outcomes for acute heart
failure patients on beta-blockers in SURVIVE.
Eur J Heart Fail 2009;11:304-311.
Silva-Cardoso J, Ferreira J, Oliveira-Soares A, et al.
Effectiveness and safety of levosimendan in clinical practice.
Rev Port Cardiol 2009;28:143-154.
De Santis V, Vitale D, Tritapepe L, et al.
Use of levosimendan for cardiogenic shock in a patient
with the apical ballooning syndrome.
Ann Intern Med 2008;149:365-367.
Parissis J, Toller W, Franco F, et al.
Levosimendan: a decade of experience in Europe built
on years of evidence.
Eur J Heart Fail 2008;(Suppl 7);234-243.
Mebazaa A. Nieminen MS, Packer M, et al.
Levosimendan vs dobutamine for patients with acute
decompensated heart failure. The SURVIVE randomized
trial.
JAMA 2007;297:1883-1891.
Parissis JT, Papadopoulos C, Nikolaou M, et al.
Effects of levosimendan on quality of life and emotional
stress in advanced heart failure patients.
Cardiovasc Drugs Ther 2007;21:263-268.
Adamopoulos S, Parissis JT, Iliodromitis EK, et al.
Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated
chronic heart failure.
Am J Cardiol 2006;98:102-106.
Dernellis J, Panaretou M.
Effects of levosimendan on restrictive left ventricular
filling in severe heart failure: A combined hemodynamic
and Doppler echocardiograpic study.
Chest 2005;128:2633-2639.
Kivikko M, Lehtonen L, Colucci WS, et al.
Sustained hemodynamic effects of intravenous
levosimendan.
Circulation 2003;107:81-86.
Follath F, Cleland JGF, Just H, et al.
Efficacy and safety of intravenous levosimendan compared
with dobutamine in severe low-output heart failure
(the LIDO study): a randomised double-blind trial.
Lancet 2002;360:196-202.
Nieminen MS, Akkila J, Hasenfuss G, et al.
Hemodynamic and neurohumoral effects of continuous
infusion of levosimendan in patients with congestive
heart failure.
J Am Coll Cardiol 2000;36:1903-1912.
Slawsky MT, Colucci WS, Gottlieb SS, et al.
Acute hemodynamic and clinical effects of levosimendan
in patients with severe heart failure.
Circulation 2000;102:2222-2227.
• RIGHT VENTRICULAR FAILURE
Russ MA, Prondzinsky R, Carter JM, et al.
Right ventricular function in myocardial infarction complicated by cardiogenic shock: improvement with levosimendan.
Crit Care Med 2009;37:3017-3023.
Yilmaz MB, Yontar C, Erdem A, et al.
Comparative effects of levosimendan and dobutamine on
right ventricular function in patients with biventricular
heart failure.
Heart Vessels 2009;24:16-21.
September 2013
Duygu H, Ozerkan F, Zoghi M, et al.
Effect of levosimendan on right ventricular systolic and
diastolic functions in patients with ischaemic heart failure.
Int J Clin Pract 2008;62:228-233.
Poelzl G, Zwick RH, Grander W, et al.
Safety and effectiveness of levosimendan in patients with
predominant right heart failure.
Herz 2008;33:368-373.
Parissis JT, Paraskevaidis I, Bistola V, et al.
Effects of levosimendan on right ventricular function in
patients with advanced heart failure.
Am J Cardiol 2006;98:1489-1492.
• INTERMITTENT ADMINISTRATION
Tuomainen PO, Magga J, Timonen P, et al.
Intermittent levosimendan treatment in patients with
severe congestive heart failure.
Clin Res Cardiol 2013;102:485-493.
Garcia-Gonzáles MJ, de Mora-Martin M,
López-Fernández S, et al.
Rationale and design of a randomized, double-blind,
placebo controlled multicenter trial to study efficacy,
security, and long term effects of intermittent repeated
levosimendan administration in patients with advanced
heart failure: LAICA study.
Cardiovasc Drugs Ther 2013;July 27: [Epub ahead of print].
Malfatto G, Della Rosa F, Villani A, et al.
Intermittent levosimendan infusions in advanced heart
failure: favourable effects on left ventricular function,
neurohormonal balance, and one-year survival.
J Cardiovasc Pharmacol 2012;60:450-455.
Papadopoulou P, Mavrogeni SI, Dritsas A, et al.
Assessment of quality of life using three activity question­
naires in heart failure patients after monthly, intermittent
administration of levosimendan during a six-month period.
Hellenic J Cardiol 2009;50:269-274.
Parle NM, Thomas MD, Dembo L, et al.
Repeated infusions of levosimendan: well tolerated and
improves functional capacity in decompensated heart
failure - a single-centre experience.
Heart Lung Circ 2008;17:206-210.
Mavrogeni S, Giamouzis F, Papadopoulou E, et al.
A 6-month follow-up of intermittent levosimendan admi­
nistration effect on systolic function, specific activity questionnaire, and arrhythmia in advanced heart failure.
J Cardiac Fail 2007;13:556-559.
Parissis JT, Adamopoulos S, Farmakis D, et al.
Effects of serial levosimendan infusions on left ventricular
performance and plasma biomarkers of myocardial injury
and neurohormonal and immune activation in patients
with advanced heart failure.
Heart 2006;92:1768-1772.
Nanas JN, Papazoglou P, Tsagalou EP, et al.
Efficacy and safety of intermittent, long-term, concomitant
dobutamine and levosimendan infusions in severe heart
failure refractory to dobutamine alone.
Am J Cardiol 2005;95:768-771.
2 (6)
Spargias KS, Anifantakis A, Papadakis M, et al.
Preliminary clinical experience with the repetitive admi­
nistration of levosimendan in patients with end-stage
heart failure.
Ital Heart J 2003;4(Suppl 2):45S-49S.
• RENAL FUNCTION
Bragadottir G, Redfors B, Ricksten SE.
Effects of levosimendan on glomerular filtration rate, renal
blood flow, and renal oxygenation after cardiac surgery
with cardiopulmonary bypass: a randomized placebocontrolled study.
Crit Care Med 2013;41:2328-2335.
Yilmaz MB, Grossini E, Silva Cardoso JC, et al.
Renal effects of levosimendan: a consensus report.
Cardiovasc Drugs Ther 2013; Aug 9: [Epub ahead of print].
Zorlu A, Yücel H, Yontar OC, et al.
Effect of levosimendan in patients with severe systolic
heart failure and worsening renal function.
Arq Bras Cardiol 2012;98:537-543.
Puttonen J, Kantele S, Kivikko M, et al.
Effect of severe renal failure and haemodialysis on the
pharmacokinetics of levosimendan and its metabolites.
Clin Pharmacokinet 2007;46:235-246.
Yilmaz MB, Yalta K, Yontar C, et al.
Levosimendan improves renal function in patients with
acute decompensated heart failure: comparison with
dobutamine.
Cardiovasc Drugs Ther 2007;21:431-435.
Zemljic G, Bunc M, Yazdanbakhsh AP, et al.
Levosimendan improves renal function in patients with
advanced chronic heart failure awaiting cardiac trans­
plantation.
J Cardiac Fail 2007;13:417-421.
CARDIAC SURGERY
Levin R, Degrange M, Del Mazo C, et al.
Preoperative levosimendan decreases mortality and the
development of low cardiac output in high-risk patients
with severe left ventricular dysfunction undergoing
coronary artery bypass grafting with cardiopulmonary
bypass.
Exp Clin Cardiol 2012;17:125-130.
Sponga S, Ivanitskaia E, Potapov E, et al.
Preoperative treatment with levosimendan in candidates for
mechanical circulatory support.
ASAIO J 2012;58:6-11.
Elahi MM, Lam J, Asopa S, et al.
Levosimendan versus an intra-aortic balloon pump in adult
cardiac surgery patients with low cardiac output.
J Cardiothorac Vasc Anesth 2011;25:1154-1162.
Lahtinen P, Pitkänen O, Pölönen P, et al.
Levosimendan reduces heart failure after cardiac surgery
– a prospective, randomized, placebo-controlled trial.
Crit Care Med 2011;39:2263-2270.
September 2013
3 (6)
Lomivorotov VV, Cherniavskiy AM, Boboshko VA, et al.
Levosimendan vs. intra-aortic balloon pump in high-risk
cardiac surgery.
Asian Cardiovasc Thorac Ann 2011;19:154-159.
Morais RJ.
Levosimendan in servere right ventricular failure following
mitral valve replacement.
J Cardiothorac Vasc Anesth 2006;20:82-84.
Brezina A, Riha H, Pirk J.
Prophylactic application of levosimendan in cardiac surgical
patients with severe left ventricle dysfunction.
Exp Clin Cardiol 2009;14:e31-34.
Petäjä LM, Sipponen JT, Hämmäinen PJ, et al.
Levosimendan reversing low output syndrome after heart
transplantation.
Ann Thorac Surg 2006;82:1529-1531.
Eriksson HI, Jalonen JR, Heikkinen LO, et al.
Levosimendan facilitates weaning from cardiopulmonary
bypass in patients undergoing coronary artery bypass
grafting with impaired left ventricular function.
Ann Thorac Surg 2009;87:448-454.
Lilleberg J, Nieminen MS, Akkila J, et al.
Effects of a new calcium sensitizer, levosimendan, on
haemodynamics, coronary blood flow and myocardial
substrate utilization early after coronary artery bypass
grafting.
Eur Heart J 1998;19:660-668.
Salmenperä M, Eriksson H.
Levosimendan in perioperative and critical care patients.
Curr Opin Anaesthesiol 2009;22:496-501.
Tritapepe L, De Santis V, Vitale D, et al.
Levosimendan pre-treatment improves outcomes in patients
undergoing coronary artery bypass graft surgery.
Br J Anaesth 2009;102:198-204.
Weis F, Beiras-Fernandez A, Kaczmarek I, et al.
Levosimendan: a new therapeutic option in the treatment
of primary graft dysfunction after heart transplantation.
J Heart Lung Transplant 2009;28:501-504.
Beiras-Fernandez A, Weis FC, Kur F, et al.
Primary graft failure and Ca2+ sensitizers after heart
transplantation.
Transplant Proc 2008;40:951-952.
Järvelä K, Maaranen P, Sisto T, et al.
Levosimendan in aortic valve surgery: cardiac performance
and recovery.
J Cardiothorac Vasc Anesth 2008;22:693-698.
Jörgensen K, Bech-Hanssen O, Houltz E, et al.
Effects of levosimendan on left ventricular relaxation and
early filling at maintained preload and afterload conditions
after aortic valve replacement for aortic stenosis.
Circulation 2008;117:1075-1081.
Levin RL, Degrange MA, Porcile R, et al.
The calcium sensitizer levosimendan gives superior results to
dobutamine in postoperative low cardiac output syndrome.
Rev Esp Cardiol 2008;61:471-479.
De Hert SG, Lorsomradee S, Cromheecke S, et al.
The effects of levosimendan in cardiac surgery patients
with poor left ventricular function.
Anesth Analg 2007;104:766-773.
Al-Shawaf E, Ayed A, Vislocky I, et al.
Levosimendan or milrinone in the type 2 diabetic patient
with low ejection fraction undergoing elective coronary
artery surgery.
J Cardiothorac Vasc Anesth 2006;20:353-357.
Braun JP, Jasulaitis D, Moshirzadeh M, et al.
Levosimendan may improve survival in patients requiring
mechanical assist devices for post-cardiotomy heart failure.
Crit Care 2006;10:R17.
ISCHAEMIC HEART DISEASE
Husebye T, Eritsland J, Müller C, et al.
Levosimendan in acute heart failure following primary
percutaneous coronary intervention treated acute STelevation myocardial infarction. Results from the LEAF trial:
a randomized, placebo-controlled study.
Eur J Heart Fail 2013;15:565-572.
Qarawani D, Cohen A, Nahir M, et al.
Facilitation of left ventricular function recovery post
percutaneous coronary intervention by levosimendan.
Int J Cardiol 2012;Oct 11: [Epub ahead of print].
Buerke M, Lemm H, Krohe K, et al.
Levosimendan in the treatment of cardiogenic shock.
Minerva Cardioangiol 2010;58:519-530.
Tsagalou EP, Kanakakis J, Anastasiou-Nana MI, et al.
Hemodynamic effects of levosimendan in acute myocardial
infarction complicated by cardiogenic shock and high
systemic vascular resistance.
Acute Card Care 2009;11:99-106.
Cianfrocca C, Pelliccia F, Pasceri V, et al.
Strain rate analysis and levosimendan improve detection
of myocardial viability by dobutamine echocardiography in
patients with post-infarction left ventricular dysfunction: a
pilot study.
J Am Soc Echocardiogr 2008;21:1068-1074.
Fuhrmann JT, Schmeisser A, Schulze MR, et al.
Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction.
Crit Care Med 2008;36:2257-2266.
Greif M, Zwermann L, Reithmann C, et al.
Levosimendan as rescue therapy in severe cardiogenic shock
after ST-elevation myocardial infarction.
Acute Cardiac Care 2008;10:185-190.
Christoph A, Prondzinsky R, Russ M, et al.
Early and sustained haemodynamic improvement with levosimendan compared to intraaortic balloon counterpulsation
(IABP) in cardiogenic shock complicating acute myocardial
infarction.
Acute Cardiac Care 2008;10:49-57.
September 2013
Duygu H, Ozerkan F, Zoghi M, et al.
Effect of levosimendan on right ventricular systolic and
diastolic functions in patients with ischaemic heart failure.
Int J Clin Pract 2008;62:228-233.
Russ MA, Prondzinsky R, Christoph A, et al.
Hemodynamic improvement following levosimendan
treatment in patients with acute myocardial infarction
and cardiogenic shock.
Crit Care Med 2007;35:2732-2739.
De Luca L, Sardella G, Proietti P, et al.
Effects of levosimendan on left ventricular diastolic function
after primary angioplasty for acute anterior myocardial
infarction: a Doppler echocardiographic study.
J Am Soc Echocardiogr 2006;19:172-177.
Garcia Gonzales MJ, Dominguez Rodriguez A.
Pharmacologic treatment of heart failure due to
ventricular dysfunction by myocardial stunning:
Potential role of levosimendan.
Am J Cardiovasc Drugs 2006;6:69-75.
De Luca L, Proietti P, Celotto A, et al.
Levosimendan improves hemodynamics and coronary
flow reserve after percutaneous coronary intervention
in patients with acute myocardial infarction and left
ventricular dysfunction.
Am Heart J 2005;150:563-568.
Michaels AD, McKeown B, Kostal M, et al.
Effects of intravenous levosimendan on human coronary
vasomotor regulation, left ventricular wall stress, and
myocardial oxygen uptake.
Circulation 2005;111:1504-1509.
Moiseyev VS, Pöder P, Andrejevs N, et al.
Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute
myocardial infarction. A randomized, placebo-controlled,
double-blind study (RUSSLAN).
Eur Heart J 2002;23:1422-1432.
INTENSIVE CARE/ANAESTHESIA
Doorduin J, Sinderby CA, Beck J, et al.
The calcium sensitizer levosimendan improves human
d­iaphragm function.
Am J Respir Crit Care Med 2012;185:90-95.
Jaber S, Jung B, Matecki S, et al.
Clinical review: Ventilator-induced diaphragmatic
dysfunction - human studies confirm animal model findings.
Critical Care 2011;15:206.
Morelli A, Donati A, Ertmer C, et al.
Levosimendan for resuscitating the microcirculation in
patients with septic shock: a randomized controlled study.
Crit Care 2010;R232. [Epub ahead of print].
Morelli A, Ertmer C, Pietropaoli P, et al.
Reducing the risk of major elective non-cardiac surgery:
is there a role for levosimendan in the preoperative
optimization of cardiac function?
Curr Drug Targets 2009;10:863-871.
4 (6)
Katsaragakis S, Kapralou A, Drimousis P, et al.
Prophylactic preoperative levosimendan administration
in heart failure patients undergoing elective non-cardiac
surgery: a preliminary report.
Hellenic J Cardiol 2009;50:185-192.
Meaudre E, Jego C, Goutorbe P, et al.
Weaning failure from mechanical ventilation due to dilated
cardiomyopathy: successful use of levosimendan.
Acta Anaesthesiol Scand 2009;53:416-417.
Alhashemi JA, Alotaibi QA, Abdullah GM, et al.
Effects of levosimendan in acute heart failure and
cardiogenic and septic shock.
J Crit Care 2008;23:450.
Pinto BB, Rehberg S, Ertmer C, et al.
Role of levosimendan in sepsis and septic shock.
Curr Opin Anaesthesiol. 2008;21:168-177.
Ponschab M, Hochmair N, Ghazwinian N, et al.
Levosimendan infusion improves haemodynamics in elderly
heart failure patients undergoing urgent hip fracture repair.
Eur J Anaesthesiol 2008;25:627-633.
Sterba M, Banerjee A, Mudaliar Y.
Prospective observational study of levosimendan and
weaning of difficult-to-wean ventilator dependent intensive
care patients.
Crit Care Resusc 2008;10:182-186.
Toller W, Knez I.
Medical support and surgery of the failing heart:
levosimendan.
Scand J Surg 2007;96:121-124.
Morelli A, Teboul J-L, Maggiore SM, et al.
Effects of levosimendan on right ventricular afterload in
patients with acute respiratory distress syndrome:
a pilot study.
Crit Care Med 2006;34:2287-2293.
Morelli A, De Castro S, Teboul J-L, et al.
Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression.
Intensive Care Med 2005;31:638-644.
PAEDIATRICS
Angadi U, Westrope C, Chowdhry MF.
Is levosimendan effective in paediatric heart failure and
post-cardiac surgeries?
Interact Cadiovasc Thorac Surg 2013:;17:710-714.
Ebade AA, Khalil MA, Mohamed AK.
Levosimendan is superior to dobutamine as an inodilator
in the treatment of pulmonary hypertension for children
undergoing cardiac surgery.
J Anesth 2013;27:334-339.
Pellicer A, Riera J, Lopez-Ortego P, et al.
Phase 1 study of two inodilators in neonates undergoing
cardiovascular surgery.
Pediatr Res 2013;73:95-103.
De Carolis MP, Piastra M, Bersani I, et al.
Levosimendan in two neonates with ischemic heart failure
and pulmonary hypertension.
Neonatology 2012;101:201-205.
September 2013
Lechner E, Hofer A, Leitner-Peneder G, et al.
Levosimendan versus milrinone in neonates and infants
after corrective open-heart surgery: A pilot study.
Pediatr Crit Care Med 2012;13:542-548.
Turanlahti M, Boldt T, Palkama T, et al.
Pharmacokinetics of levosimendan in pediatric patients
evaluated for cardiac surgery.
Pediatr Crit Care Med 2004;5:457-462.
Ricci Z, Garisto C, Favia I, et al.
Levosimendan infusion in newborns after corrective surgery
for congenital heart disease: randomized controlled trial.
Intensive Care Med 2012;38:1198–1204
META-ANALYSIS
Suominen PK.
Single-center experience with levosimendan in children
undergoing cardiac surgery and in children with decompensated heart failure.
BMC Anesthesiol 2011;Oct 5:11:18.
Lobo Martínez P, Oulego Erroz I, Gautreux Minaya S, et al.
Treatment of acute heart failure using levosimendan for a
patient with dilated cardiomyopathy, chronic renal failure,
and hypertension.
Pediatr Cardiol 2011;32:1012-1016.
Bravo MD, López P, Cabañas F, et al.
Acute effects of levosimendan on cerebral and
systemic perfusion and oxygenation in newborns:
an observational study.
Neonatology 2010;99:217-223.
Di Chiara L, Ricci Z, Garisto C, et al.
Initial experience with levosimendan infusion for pre­
operative management of hypoplastic left heart syndrome.
Pediatr Cardiol 2010;31:166-167.
5 (6)
Harrison RW, Hasselblad V, Mehta RH, et al.
Effect of levosimendan on survival and adverse events after
cardiac surgery: a meta-analysis.
J Cardiothoracic Vasc Anesth 2013; Sept 16:[Epub ahead of
print].
Landoni G, Biondi-Zoccai G, Greco M, et al.
Effects of levosimendan on mortality and hospitalization.
A meta-analysis of randomized controlled studies.
Crit Care Med 2012;40:634-646.
Maharaj R, Metaxa V.
Levosimendan and mortality after coronary revasculari­
sation: a meta-analysis of randomised controlled trials.
Crit Care 2011;15:R140.
Zangrillo A, Biondi-Zoccai G, Mizzi A, et al.
Levosimendan reduces cardiac troponin release after cardiac
surgery: a meta-analysis of randomized controlled studies.
J Cardiothorac Vasc Anesth 2009;23:474-478.
HEALTH ECONOMICS
Momeni M, Rubay J, Matta A, et al.
Levosimendan in congenital cardiac surgery:
a randomized, double-blind clinical trial.
J Cardiothorac Vasc Anesth 2011;25:419-424.
Lucioni C, D’Ambrosi A, Mazzi S, et al.
Economic evaluation of levosimendan versus dobutamine
for the treatment of acute heart failure in Italy.
Adv Ther 2012;29:1037-1050.
Margossian R.
Contemporary management of pediatric heart failure.
Expert Rev Cardiovasc Ther 2008;6:187-197.
Fedele F, D´ambrosi A, Bruno N, et al.
Cost-effectiveness of levosimendan in patients with acute
heart failure.
J Cardiovasc Pharmacol 2011;58:363-366.
Osthaus WA, Boethig D, Winterhalter M, et al.
First experiences with intraoperative levosimendan in
pediatric cardiac surgery.
Eur J Pediatr 2009:168;735-740.
Lechner E, Moosbauer W, Pinter M, et al.
Use of levosimendan, a new inodilator, for postoperative
myocardial stunning in a premature neonate.
Pediatr Crit Care Med 2007;8:61-63.
Egan JR, Clarke AJ, Williams S, et al.
Levosimendan for low cardiac output: a pediatric
experience.
Intensive Care Med 2006;21:183-187.
Namachivayam P, Crossland DS, Butt WW, et al.
Early experience with levosimendan in children with
ventricular dysfunction.
Pediatr Crit Care Med 2006;7:445-448.
Braun JP, Schneider M, Kastrup M, et al.
Treatment of acute heart failure in an infant after cardiac
surgery using levosimendan.
Eur J Cardiothorac Surg 2004;26:228-230.
De Lissovoy G, Fraeman K, Teerlink JR, et al.
Hospital costs for treatment of acute heart failure:
economic analysis of the REVIVE II study.
Eur J Health Econ 2010;11:185-193.
MISCELLANEOUS / REVIEWS
Rognoni A, Lupi A, Cavallino C, et al.
Levosimendan preoperative.
Curr Pharm Des 2013;19:3974-3978.
Papp Z, Edes I, Fruhwald S, et al.
Levosimendan: molecular mechanisms and clinical implications consensus of experts on the mechanisms of action of
levosimendan.
Int J Cardiol 2012;159:82-87.
Toller W, Algotsson L, Guarracino F, et al.
Perioperative use of levosimendan: Best practice in operative settings.
J Cardiothorac Vasc Anesth 2013;27:361-366.
Mebazaa A, Pitsis AA, Rudiger A, et al.
Clinical review: practical recommendations on the management of perioperative heart failure in cardiac surgery.
Critical Care 2010;14:201.
September 2013
Follath F.
Newer treatments for decompensated heart failure:
focus on levosimendan
Drug Des Devel Ther 2009;3:73–78.
Nieminen MS, Pollesello P, Vajda G, et al.
Effects of levosimendan on the energy balance:
preclinical and clinical evidence.
J Cardiovasc Pharmacol 2009;53:302-310.
Parissis JT, Rafouli-Stergiou P, Paraskevaidis I, et al.
Levosimendan: from basic science to clinical practice.
Heart Fail Rev 2009;14:265-275.
Puttonen J, Kantele S, Ruck A, et al.
Pharmacokinetics of intravenous levosimendan and its
metabolites in subjects with hepatic impairment.
J Clin Pharmacol 2008;48:445-454.
Pollesello P, Papp Z.
The cardioprotective effects of levosimendan:
preclinical and clinical evidence.
J Cardiovasc Pharmacol 2007;50:257-263.
sim/2013.09/82
Kleber FX, Bollmann T, Borst MM, et al.
Repetitive dosing of intravenous levosimendan improves
pulmonary hemodynamics in patients with pulmonary
hypertension: results of a pilot study.
J Clin Pharmacol 2009;49:109-115.
6 (6)
www.orionpharma.se – www.orionpharma.no | www.simdax.com – www.simdax.se – www.simdax.no